Form 4: ADMA Biologics CEO Adam Grossman Reports Stock Transaction Following RSU Vesting

ADMA Biologics CEO Adam Grossman reported a transaction involving the withholding of shares to cover taxes upon the vesting of restricted stock units, while also disclosing his beneficial ownership of common stock through various entities.

Summary

• Adam Grossman, the President and CEO of ADMA Biologics, filed a Form 4 detailing a transaction on December 31, 2024.
• The transaction involved the withholding of 14,343 common stock shares to cover tax obligations related to the vesting of restricted stock units (RSUs).
• This was not an open market sale of securities.
• Following the transaction, Grossman directly owns 1,974,664 shares of common stock.
• Grossman also indirectly owns 1,143,426 shares through Areth, LLC, and 580,957 shares through Hariden, LLC.
• The reported direct holdings include previously granted RSUs that are vesting over time and prior purchases.
• The RSUs are vesting quarterly on each annual anniversary of the grant date over four years, subject to continued service.

Sentiment

Score: 7

Explanation: The document is a routine filing and does not indicate any positive or negative sentiment. It is a neutral disclosure of insider transactions.

Positives

• The document provides transparency into the stock ownership of the company's CEO.
• The vesting of RSUs indicates a long-term incentive structure for the CEO.
• The CEO's significant holdings demonstrate a strong alignment with shareholder interests.

Risks

• The document does not indicate any specific risks.
• The withholding of shares for tax purposes is a standard practice and does not pose a risk to the company.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, including those in the biotechnology sector.
• The vesting schedules of RSUs are typical for executive compensation packages in the industry, often vesting over a period of four years.
• The use of LLCs for holding shares is also a common practice among executives for personal financial management.

Stakeholder Impact

• The transaction has a neutral impact on shareholders as it is a standard practice related to executive compensation.
• The disclosure provides transparency to stakeholders regarding the CEO's stock ownership.

Key Dates

Keywords

ADMA Biologics, Adam Grossman, Form 4, stock transaction, restricted stock units, RSU, beneficial ownership, insider trading, tax withholding